Ikena Oncology

The 2025 transaction separated Ikena's legacy oncology programs into a privately held spin-out and merged the remaining shell with Inmagene Biopharmaceuticals. The surviving Nasdaq company was renamed ImageneBio and now focuses exclusively on immunology via the anti-OX40 antibody IMG-007. This architecture means the entity allocators previously tracked as an oncology play is no longer deploying capital toward cancer therapeutics.

IMG-007 is an investigational anti-OX40 monoclonal antibody with an extended half-life. ImageneBio states it inhibits OX40 receptor signaling without depleting T cells — a design claim intended to improve the safety and dosing convenience profile relative to prior OX40-targeting attempts. The company has not published head-to-head clinical data against other OX40 or OX40L agents.

ImageneBio describes a pipeline targeting immunological, autoimmune, and inflammatory diseases. A May 2025 KOL event outlined potential application in alopecia areata. No registration-pathway indication has been formally declared in SEC filings cited through mid-2026.

ImageneBio is not a fund or an investment vehicle — it is a publicly traded clinical-stage operating company. All internal resources support IMG-007's clinical advancement. A $30 million private placement in April 2026 provided near-term operating runway.

ImageneBio has not publicly identified its CEO, CIO, or board chair in currently available website disclosures. The management team and board composition are not surfaced in the firm's primary investor-facing materials, which is atypical for a Nasdaq-listed biotech and may reflect post-merger transition.